COMMUNIQUÉS West-GlobeNewswire

Une analyse « Late Breaking » démontre les caractéristiques associées à la survie globale à long terme des patients avec un adénocarcinome pancréatique métastatique traités par Onivyde®
31/05/2025
L’essai de Phase III NAPOLI 3 est la plus grande étude interventionnelle réalisée à ce jour avec la plus longue période de suivi des patients avec un adénocarcinome pancréatique métastatique 1 . L’analyse post-hoc de l’ [...]
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
31/05/2025
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma 1 Post-hoc analysis of NAPOLI 3 study determined characteristics associated with [...]
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
31/05/2025
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing deep and durable [...]
ImPact Biotech Presents Interim Analysis from Phase 3 ENLIGHTED Study of Padeliporfin VTP in LG UTUC at ASCO 2025
31/05/2025
– Complete response (CR) observed in 73% (27/37) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) – – Padeliporfin VTP treatment continues to be [...]
Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
31/05/2025
26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver metastases Deep and durable responses ongoing for up to 37 [...]
Harbinger Health Showcases Multi-Cancer Early Detection Performance in High-Risk Populations at ASCO 2025
31/05/2025
Reflex blood-based multi-cancer early detection (MCED) test demonstrated clinically meaningful per-cancer Positive Predictive Value (PPV) and early-stage sensitivity for multiple cancers with elevated incidence and [...]
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
31/05/2025
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen [...]
Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
31/05/2025
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001) Libtayo also demonstrated 80% and 65% reductions in the risk of locoregional and distant [...]
New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
31/05/2025
The Itovebi TM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA -mutated HR-positive, HER2-negative advanced breast cancer, compared with palbociclib and fulvestrant alone 1 [...]
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
31/05/2025
More than half of residents with tardive dyskinesia (TD) residing in long-term care (LTC) settings do not receive standard of care treatment, and one-quarter are left untreated LTC residents are often given a broader [...]
Early Warning Press Release Respecting the Acquisition of Common Shares of RAMM PHARMA Corp.
31/05/2025
TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- Jack Burnett (" CEO ") today announced that he has filed an early warning report (the " Early Warning Report ") under National Instrument 62-103 – The Early Warning System and [...]
Hydreight Reports 34% Year-Over-Year Q1 Revenue Growth, Improvement in Bottom Line Results, and Delivers Strong Performance Across Verticals
31/05/2025
“It was an outstanding quarter. We exceeded our Q1 projections with approximately 34% YOY growth from our first two verticals, a clear sign that our strategy is working. We also secured new customers for VSDHOne, [...]
IBA – ACQUISITION D’ACTIONS PROPRES - FIN DU PROGRAMME DE RACHAT D’ACTIONS
30/05/2025
Publication immédiate – 30 mai 2025 Louvain-la-Neuve, Belgique, 30 mai 2025 - Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam [...]
Iba – Acquisition of Own Shares - Completion of the Share Buyback Program
30/05/2025
Immediate Release – May 30 th , 2025 Louvain-la-Neuve, Belgium, May 30 th , 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam [...]
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30/05/2025
VANCOUVER, British Columbia and BOSTON, May 30, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering [...]
Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025
30/05/2025
Company to host video webcast at 8:00 a.m. ET on Monday, June 2, 2025 WATERTOWN, Mass., May 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a [...]
NurExone Announces Clinical Trial Plans for Acute Spinal Cord Injury Therapy at Annual Meeting of American Spinal Injury Association
30/05/2025
TORONTO and HAIFA, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”) is pleased to announce that Professor Nahshon Knoller M.D., [...]
Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights
30/05/2025
Company continues to progress both REYOBIQ™ radiotherapeutic clinical trials and CNSide® CSF assay platform launch readiness HOUSTON, May 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or [...]
Publication relative à des notifications de transparence
30/05/2025
INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 30 mai 2025 , 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à la [...]

Pages